Showing 631-640 of 839 results for "".
- Dr. Louis R. Pasquale Winner of the Glaucoma Foundation's 2023 Robert Ritch Awardhttps://modernod.com/news/dr-louis-r-pasquale-winner-of-the-glaucoma-foundations-2023-robert-ritch-award/2481629/Louis R. Pasquale, MD, FARVO, has been named the 2023 recipient of The Glaucoma Foundation’s (TGF) Robert Ritch Award for Innovation and Excellence in Glaucoma. Created in 2008, the award recognizes the contributions of individuals who have played a significant and unique role in promoting
- Salvat Laboratories Presents Phase 3 Clinical Trials Results of Clobetasol Nanoemulsion for Treating Inflammation and Pain After Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-presents-phase-3-clinical-trials-results-of-clobetasol-nanoemulsion-for-treating-inflammation-and-pain-after-ocular-surgery/2481604/Salvat Laboratories announced the results of phase 3 clinical trials of its ophthalmic corticosteroid at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The studies’ global coordinator, Andrew Schwartz, MD, presented a poster outlinin
- Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)https://modernod.com/news/cellusion-announces-first-patient-transplanted-ipsc-derived-corneal-endothelial-cell-substitute-cls001/2481493/An iPS cell-derived corneal endothelial cell substitute (CLS001) was transplanted to the first patient, according to Cellusion. Research collaborator, Shigeto Shimmura, MD, PhD, Professor of Fujita Health University and Keio University in Japan, provided details of the procedure&nb
- Pioneers in Retinal Gene Therapies Awarded International Harrington Prizehttps://modernod.com/news/pioneers-in-retinal-gene-therapies-awarded-international-harrington-prize/2481453/The tenth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Jean Bennett, MD, PhD, the F.M. Kirby Emeritus Professor of Ophthalmology and Cell and Developmental Biology at the Perelman School of Medicine at the University of Pennsylvania;
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free 
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetingshttps://modernod.com/news/ocuphire-announces-apx3330-phase-2-data-presentations-at-retina-meetings/2481416/Ocuphire Pharma announced two presentations featuring efficacy and safety results from the company’s recently completed ZETA-1 phase 2 trial of oral APX3330 in diabetic retinopathy (DR) at two medical meetings in February. Peter Kaiser, MD, Professor of Ophthalmology at the C
- Radiance Therapeutics to Present at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/radiance-therapeutics-to-present-at-glaucoma-360-new-horizons-forum/2481398/Radiance Therapeutics announced that Laurence Marsteller, MD, Chief Executive Officer, will present the company at the Glaucoma Research Foundation headline event, Glaucoma 360 New Horizons 2023, that will take place on February 3, 2023 in San Francisco. The Radiance Therapeut
- Clearside Biomedical Announces Leadership Changeshttps://modernod.com/news/clearside-biomedical-announces-leadership-changes/2481386/Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, MD, will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ci
- Eyenovia: Positive Evidence that Optejet Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Dropshttps://modernod.com/news/eyenovia-positive-evidence-that-optejet-delivery-technology-decreased-inflammation-from-preserved-glaucoma-solutions-compared-to-drops/2481349/Eyenovia announced results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatm